BIOMAT Database Logo BIOMAT Database Logo

Characterisation and properties of a small cell lung cancer cell line and xenograft WX322 with marked sensitivity to alpha-interferon. 1991

S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, UK.

Controversy exists as to whether interferons usefully influence the growth of epithelial carcinomas. A small cell lung carcinoma (SCLC) cell line, WX322, has been derived which is greater than 1000-fold more sensitive to alpha-interferon (IFN) when grown in agar than other reported SCLC cell lines. The WX322 line has been characterised to prove its epithelial origin and its chemosensitivity compared with that of the NCI-H69 small cell line. The WX322 cell line expresses neuroendocrine and epithelial markers and possesses a morphology consistent with SCLC origin. A concentration of 5 IU ml-1 of IFN produced 50% inhibition of colony formation in agar in the WX322 line, whereas a concentration of greater than 10(5) IU ml-1 was required to produce a comparable effect with the NCI-H69 cell line. In contrast, WX322, possessed similar sensitivity to NCI-H69 cells when exposed to a range of cytotoxic agents. Analysis of the cell cycle indicated that IFN increased the percentage of cells in the G0/G1 phase for the WX322 cell line but increased the percentage in S phase for the NCI-H69 line. Growth of the xenograft, from which the cell line was derived, was also inhibited by IFN at doses greater than 10(5) IU/mouse/day. The WX322 cell line whether grown in agar or as a xenograft shows an unusually high sensitivity to IFN and provides an interesting model for studying mechanisms of IFN cytotoxicity to epithelial cells.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008808 Mice, Inbred CBA An inbred strain of mouse that is widely used in BIOMEDICAL RESEARCH. Mice, CBA,Mouse, CBA,Mouse, Inbred CBA,CBA Mice,CBA Mice, Inbred,CBA Mouse,CBA Mouse, Inbred,Inbred CBA Mice,Inbred CBA Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell

Related Publications

S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
Characterisation of a vindesine-resistant human small-cell lung cancer cell line.
July 1993, British journal of cancer,
S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines.
June 1993, Anti-cancer drugs,
S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
August 1995, British journal of cancer,
S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
January 1998, Anticancer research,
S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy.
January 1993, Journal of cancer research and clinical oncology,
S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer.
January 2016, Contemporary oncology (Poznan, Poland),
S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer.
October 1995, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line.
January 2000, Oncology reports,
S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor.
August 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
S P Langdon, and G J Rabiasz, and L Anderson, and A A Ritchie, and R J Fergusson, and F G Hay, and E P Miller, and P Mullen, and J Plumb, and W R Miller
Interferon-alpha 2b modulation of doxorubicin sensitivity in a multidrug resistant cell line.
September 2001, Journal of experimental & clinical cancer research : CR,
Copied contents to your clipboard!